Hysterectomy Procedure Tied to Worse Cancer Outcomes

THURSDAY, Sept. 19, 2019 -- Women who must have their uterus removed should be wary of a procedure called uncontained uterine power morcellation, Yale University researchers warn.

This once common surgical option for hysterectomy or myomectomy (removal of uterine fibroids) has been linked to worse outcomes for patients with undiagnosed uterine cancer at the time of surgery.

Recarbrio OK'd for Complicated Urinary Tract, Intra-Abdominal Infections

THURSDAY, July 18, 2019 -- The antibacterial drug product Recarbrio (imipenem, cilastatin, and relebactam) has been approved to treat complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in adults, the U.S. Food and Drug Administration announced.

Recarbrio, a three-drug combination injection, is intended to be used for patients who have limited or no alternative antibacterial drugs to treat their infection, Ed Cox, M.D., M.P.H., director for the Office of Antimicrobial Products in the FDA Center for Drug Evaluation and Research, noted in an FDA release. The recommended dose is 1.25 g administered by intravenous infusion for 30 minutes every six hours in patients aged 18 years or older with creatinine clearance of at least 90 mL/minute.